Reformulation. As of the Effective Date, Xxxxxx shall not distribute, sell or offer for sale Products in California unless (a) the Products contain no more than 100 parts per million (0.01%) of lead (“Reformulated Products”), or (b) the Products are distributed, sold, or offered for sale with a clear and reasonable warning as described below in Section 2.2.
Reformulation. Dyax shall remain responsible for any activities relating to the reformulation of the Product, including those that are conducted in connection with the EMA approved Pediatric Investigational Plan.
Reformulation. As of the Effective Date, Harbor Freight shall not manufacture or distribute the Products for sale in California unless (a) the Products contain no more than 1,000 parts per million (0.1%) of DEHP, DBP, or DINP, and no more than 100 parts per million (0.01%) of Lead (“Reformulated Product”), or (b) the Product is distributed, sold, or offered for sale with a clear and reasonable warning as described below in Section 2.2. The only Products excluded from this requirement are those that have already been distributed to California retailers as of October 31, 2020
Reformulation. Should Buyer by reason of product reformulation, process change or similar reason, deem it necessary to reduce or discontinue purchases of Materials or services covered by this Agreement, Buyer shall have the right to reduce or discontinue Seller's shipments hereunder, provided that Buyer notifies Seller as soon as it has reasonable expectation of such change and further provided any such reduction or discontinuance is in the same proportion as applied by Buyer to other suppliers, if any, supplying materials or services to Buyer, and provided further, that Buyer has given Seller not less than ninety (90) days' notice of such reduction or discontinuance. If Buyer needs to reformulate in less than ninety (90) days, Seller will make a good faith effort to accommodate Buyer's requirements.
Reformulation. Notwithstanding anything to the contrary contained herein, any Development or other activities relating to the reformulation of Product (including the activities conducted under any Development Plan) shall be conducted by Dyax. Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such omission.
Reformulation. As of the Effective Date, NOCO shall: (i) sell, or purchase for sale, or distribute for sale in California, “Reformulated Products” pursuant to this Section 2.1; or (ii) sell, or purchase for sale, or distribute for sale in California Products that carry the Proposition 65 warnings specified in Section 2.2 below. “
Reformulation. We reformulate the collision avoidance constraints as pos (Ry(k)) ∩ pos (Ry(k)) = ∅ and (19a) We now present a numerical study to illustrate the utility of our proposed method for uncertainty-aware planning in multi-agent scenes. As part of our codebase, we contribute a framework for generating interactive scenes. We created this because we found that, in preliminary experiments with traffic data [53], [54], traffic agents mostly follow predefined paths with little interaction. Our code is open-source1. We implement zonotopes in python using the numpy package [55]. We solve (7) using the Interior Point Method (IPM) solver cyipopt2. The cost and constraints gradients are com- puted via PyTorch [52] automatic differentiation. We generate our dataset using the environment shown in Figs. 2 and 3. The goal is to navigate a hallway while avoiding 10 non-ego agents. All agents are modeled as double integrators subject to nonlinear forces (note that Trajectron++ [5] can readily handle more complex nonlinear e y i dynamics; we deliberately chose dynamics that allowed us pose(R (k)) ∩ Xobs = ∅ (19b) · · · − for each k = 0, , kf 1. y
Reformulation. As of the 60th day after the Effective Date, and continuing thereafter, Products that ASOS manufactures, imports, distributes, sells, or offers for sale in California shall either: (a) contain no more than 1,000 parts per million (0.1%) of DEHP (“Reformulated Products”), or (b) be distributed, sold, or offered for sale with a clear and reasonable warning as described below in Section 2.3.
Reformulation. In addition to the obligation to warn under Section 2.3, Invacare represents it has begun reviewing the option to reformulate under Section 2.2 to meet a concentration limit of 1000 parts per million (0.1%) for DEHP in all accessible components of the Products manufactured, imported or sold in California on and after the Compliance Date subject to commercial feasibility. For purposes of this Section 2.2, commercial feasibility refers to the following material factors: (1) the availability of other materials that do not incorporate other substances regulated under Proposition 65 (“New Materials”); (2) performance characteristics, including efficacy, durability, and stability, of any New Materials or the resulting product; (3) the availability and reliability of the supply of New Materials; and (4) whether there are any material cost considerations for the use of New Materials. If Invacare’s reasonable efforts lead to the commercial feasibility to meet the reformulation standard referenced in Section 2.2.2 for a subset of Products, Invacare may elect to reformulate such products.
Reformulation. As of the Effective Date, Daiso shall not distribute, sell or offer for sale Products in California unless (a) the Products contain no more than 100 parts per million (0.01%) of Lead, and the Products produce a test result no higher than 1.0 microgram of Lead based on a wipe sample collected using NIOSH Method 9100 or equivalent (“Reformulated Products”), or (b) the Products are distributed, sold, or offered for sale with a clear and reasonable warning as described below in Section 2.2.
